TABLE 2

Influence of the diagnostic criteria on the incidence of AKI during intravenous AmB use in 162 hospitalized adults treated at a university hospital, stratified by type of AmB preparation

AKI criteriaNo./total no. (%) (n = 162)No./total no. (%) with AmB preparation type:P value
Deoxycholate (n = 120)Liposomal (n = 42)
Binarya
    NT2×45/162 (27.8)38/120 (31.7)7/42 (16.7)0.062
    NT0.573/162 (45.1)59/120 (49.2)14/42 (33.3)0.076
    RIFLEbin83/162 (51.2)65/120 (54.2)18/42 (42.9)0.207
    AKINbinb72/137 (52.6)55/102 (53.9)17/35 (48.6)0.584
    KDIGObin95/162 (58.6)72/120 (60.0)23/42 (54.8)0.553
KDIGO stagec
    150/162 (30.9)34/120 (28.3)16/42 (38.1)0.290
    230/162 (18.5)25/120 (20.8)5/42 (11.9)
    315/162 (9.3)13/120 (10.8)2/42 (4.8)
  • a NT2×, traditional nephrotoxicity criterion of an SCr increase ≥2× over baseline; NT0.5, traditional nephrotoxicity criterion of an absolute SCr increase of ≥0.5 mg/dl over baseline; RIFLE, risk, injury, failure, loss, and end stage; RIFLEbin, SCr increase of ≥1.5× over baseline; AKIN, Acute Kidney Injury Network; AKINbin, absolute SCr increase of ≥0.3 mg/dl over baseline; KDIGO, Kidney Diseases Improving Global Outcomes; KDIGObin, absolute SCr increase of ≥0.3 mg/dl or ≥1.5× over baseline.

  • b Unable to use AKIN criteria in 25 patients due to the 48-h requirement.

  • c Numbers represent the maximum stage. Some patients with KDIGO stages 2 or 3 passed through stage 1, but they were classified as the maximum stage they reached.